From patients with untreated Graves' disease 11 sera showing high cAMP release in the FRTL-5 cell assay were studied for relative proportions of kappa or lambda Ig molecules showing cAMP releasing activity. Immunoabsorption of y-globulins was performed using monoclonal murine anfi-kappa or antilambda antibodies linked to cyanogen bromide-activated sepharose. Specific kappa-or lambda-adsorbed fractions were also eluted from immunoabsorbents using chaotrophic thiocyanate buffers and equilibrated with pH 7.4 low salt buffer by dialysis. Immunoabsorption and elution experiments showed that five Graves' sera contained predominant cAMP-releasing activity within lambda Ig fractions, whereas two Graves' sera showed predominant cAMP-releasing activity in kappa Ig fractions. Four sera showed cAMP release approximately equally divided between kappa and lambda Ig both after immunoabsorption and specific anti-kappa or anti-lambda eluates were studied.
Introduction
A selected number of human antibodies appear to exhibit various degrees of natural clonal restriction. Among the first to be recognized were the 1gM cold agglutinins which have long been defined as predominantly IgM kappa antibodies (1) (2) (3) .
Many naturally occurring antibodies to human factor VIII have been restricted largely to the relatively rare IgG-4 subclass (4, 5) , and recently human monoclonal IgM rheumatoid facReceivedfor publication 7 January 1988 and in revisedform 10 May 1988. tors of kappa type appear to share a number of interesting structural and idiotypic similarities (6) (7) (8) (9) (10) . In 1986, Knight and co-workers ( 11) reported that human sera derived from patients with high levels of long-acting thyroid stimulator (LATS)' activity showed an almost complete lambda Ig molecule restriction. 10 out of 11 such sera appeared to contain LATS or LATS-protector (LATS-P) antibody of primarily lambda class as established by selective immunoabsorption. These authors suggested that this was evidence in favor of the "forbidden clone" hypothesis. Earlier, a report by Zakarija (12) had also provided evidence for what appeared to be relative oligoclonal restriction in autoantibodies occurring in the serum ofGraves' disease patients. The present study was therefore directed at an examination of thyroid-stimulating antibodies (TsAb) as measured in a sensitive in vitro bioassay for their possible kappa or lambda restriction. This was initiated because it seemed important to investigate further the striking results obtained with the in vitro LATS bioassay. Moreover, a number of observations regarding anti-thyrotropin-stimulating hormone (TSH) receptor antibodies support the concept that such -globulins might include a spectrum ofdifferent but related specificities (13) (14) (15) (16) . In addition, during the present study, genomic DNA from a large sample of patients with Graves' disease was examined directly using restriction fragment length polymorphism (RFLP) analyses in an attempt to uncover possible linkage disequilibrium in germ-line immunoglobulin lambda genes among such patients which might somehow be related to the restriction of TsAb activity to IgG of lambda type.
Methods
Genomic DNA was prepared from peripheral blood samples collected from 119 Graves' disease patients attending thyroid clinics at four London Hospitals: Royal Free, Guy's, St. Thomas', and University College. In addition, a group of 39 patients manifestating severe Graves' ophthalmopathy, followed in the Thyroid Clinic ofMoorfields Eye Hospital, were also studied. A second control group of 29 patients with primary autoimmune hypothyroidism followed at Royal Postgraduate Medical School, Hammersmith Hospital, was diagnosed as primary hypothyroidism requiring replacement therapy with thyroxine and showed presence of elevated thyroglobulin or microsomal antibodies. None had ever shown a thyrotoxic phase to their illness.
DNA was extracted as previously described (17) from 10-ml samples of blood collected in EDTA tubes. Briefly, cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1% (vol/vol) Triton X-100, 0.32 M sucrose) at 4VC followed by centrifugation at 1,000 g for 10 min. The pelleted nuclei were resuspended in 5 ml of resuspension buffer (0.075 M NaCl, 0.029 M EDTA, pH 8.0) followed by immediate addition of 0.5 ml 5% (wt/vol) SDS containing 2 mg/ml of proteinase K. The mixture was incubated for 2-4 h at 370C and then extracted twice with redistilled phenol saturated with 20 mM Tris pH 8.0 and twice with chloroform-isoamylalcohol (24:1) . The DNA was precipitated from the aqueous phase by addition ofNaOAc to 300 mM and of 2 vol of ethanol, and was redissolved at I mg/ml in 10 mM Tris-HCl pH 7.5, 1 mM EDTA buffer (TE).
Isolation of lymphocytes from Graves' disease thyroid glands. In three instances DNA from peripheral blood mononuclear leukocytes (PBMC) was compared with that simultaneously collected from lymphocytes infiltrating fresh thyroid glands removed at therapeutic subtotal thyroidectomy. In these cases, the fresh thyroid tissue collected at the operating theatre in ice-cold sterile saline was immediately minced in a sterile petri dish on ice in the presence of 20 ml of RPMI plus 10% fetal calf serum (FCS). The minced tissues were strained through gauze and a wire mesh tea strainer into a sterile beaker, and the 40 ml of strained material was spun at 1,400 rpm and 4VC for 10 min. Cell pellets were then resuspended in 10 ml of fresh RPMI (23) . y-Globulins precipitated from serum using 15% polyethylene glycol 4000 were used in the FRTL-5 cell bioassay using the protocol previously described (24, 25 4000 and put on immunoabsorbent columns for 1-2 h, followed by washing with 0.1 M pH 7.4 phosphate-buffered saline (PBS). The absorbed y-globulins were then eluted with 3 M sodium thiocyanate and eluates concentrated and dialyzed to equilibrate them with PBS, pH 7.4. Absorbed and eluted y-globulin preparations were adjusted to the same protein concentration before assay in the FRTL-5 cell system. Samples were assayed before and after immunoabsorption. Completeness of immunodepletion after absorption procedures was monitored by ELISA determination using a standard curve established with known amounts of kappa and lambda Ig. Control immunoabsorption procedures included passage of the same Graves' sera over Sepharose linked to a monoclonal mouse IgG without defined antibody activity. After washing such control columns with PBS, eluates were prepared in the same fashion as with the specific anti-kappa or anti-lambda immunoabsorbents. These controls were directed at estimating the relative amounts of nonspecific adsorption involved in the immunodepletion procedures.
Results
Absorption studies. Graves' disease patients' sera that were strongly positive in the cAMP-release FRTL-5 cell bioassay were absorbed for kappa or lambda molecules using the monoclonal murine anti-kappa or anti-lambda antibodies linked to sepharose. Results of such immunoabsorption procedures showed remarkable light chain class (lambda or kappa Ig restriction) of immunoglobulins producing cAMP release in some Graves' sera. 5 of 11 Graves' sera showed cAMP-releasing activity predominantly associated with Ig lambda molecules. Examples of representative relative kappa or lambda immunodepletion in parallel with FRTL-5 cell line assay results are shown for Graves' serum A in Table I and Fig. 1 . Kappa and lambda ELISA quantitations showed virtually complete elimination (99%) of respective kappa or lambda molecules immunodepleted with < 1% residual contamination of depleted class molecules. The cAMP response of 800% above normal in the control-absorbed Graves' patient sample was markedly diminished following lambda immunodepletion, whereas absorption with anti-kappa immunoabsorbents actually resulted in an increased potency to 1,200% above normal. Since the kappa-absorbed sample was relatively enriched for lambda, this increased potency would be expected. Eluates from the control immunoabsorbent columns which contained undetectable IgG, did not stimulate significantly above the control. However, eluates from the antilambda immunoabsorbent induced > 1,200% above normal cAMP release. In parallel, the anti-kappa immunoabsorbent eluate showed only slight activity. This same profile of results was reproduced in entirely different experiments with a fresh serum sample from this patient using complete repetition of the entire immunodepletion and cAMP assay procedure. Two other Graves' disease sera (F and G in Table II) with high cAMP-releasing activity also showed a completely consistent overwhelming lambda predominance in cAMP-releasing activity confirmed in the same pattern as that shown for Graves' serum A in Fig. 1 . Moreover, the same lambda predominance pattern of cAMP release was completely reproducible when the entire process-immunoabsorption, elution, and cAMPreleasing assays-was repeated in different experiments. Since in the three sera where anti-lambda depletion resulted in almost complete elimination of cAMP-releasing activity, it seemed possible that some additional oligoclonality might be present in lambda-enriched fractions, these latter materials were examined using both high-resolution agarose electrophoresis and isoelectric focusing procedures. A number of experiments were performed using lambda-enriched (kappa-depleted) fractions from patients showing predominant lambda cAMP-releasing activity. These showed a broad electrophoretic distribution of residual Ig lambda molecules and no clear evidence for oligoclonal or monoclonal lambda Ig components. Therefore, these results provided no clear evidence for concomitant H-chain subgroup or further detectable oligoclonal Ig restriction in the immunodepleted Graves' samples studied.
In two other Graves' sera, immunodepletion of kappa or lambda Ig also confirmed lambda Ig predominance for cAMP releasing activity (Graves' patients B and H, Tables I and II) . Both anti-kappa and anti-lambda immunodepletion produced residual fractions which were 95-96% enriched for the opposite Ig class. Almost complete depletion of lambda resulted in disappearance of significant cAMP release by the absorbed sample whereas depletion of kappa Ig molecules resulted in apparent relative increase in cAMP release.
In two Graves' sera, immunodepletion studies indicated a predominant kappa Ig TsAb activity. An example of this is shown in Fig. 2 and Table I (Graves' serum C). It can be seen that virtual complete immunodepletion of lambda Ig molecules increased TsAb activity, whereas anti-kappa immunodepletion which again was virtually complete (99% lambda) resulted in complete loss of activity. Results with eluates from the specific immunoabsorbents once again reflected the same kappa predominance, however, there was moderate but significant cAMP release in the anti-lambda eluate that contained 99% lambda Ig. A second Graves' serum (data not shown) gave almost identical results, which were reproduced on two different occasions.
Four Graves' sera showed clearcut TsAb activity in both kappa and lambda enriched fractions. Representative data are shown in Fig. 3 and Table I (Graves' patient D). Neither anti- Studies with eluates reflected clearcut kappa predominance, however, moderate cAMP release was also recorded with the anti-lambda eluate.
lambda nor anti-kappa absorptions produced dramatic falls in cAMP release (Fig. 3) Figure 3 . cAMP release using a Graves' serum (patient D) -y-globulin with activity in both kappa and lambda fractions. In this experiment neither anti-lambda nor anti-kappa absorptions produced major falls in cAMP release. In parallel specific anti-kappa and anti-lambda eluates showed moderately strong relative levels of cAMP-releasing activity.
ing comparisons. Taub et al. (20) In two of the three samples in which both peripheral blood leukocyte DNA and thyroid gland lymphocyte DNA were compared in this manner, a good yield of highly purified thyroid lymphocytes was obtained. When genomic DNA obtained from peripheral blood samples was compared with DNA prepared from lymphocytes actually isolated from the same Graves' disease patients' thyroid glands removed at surgery, no evidence for lambda gene rearrangement within thyroid lymphocytes was obtained. The germ-line DNA from peripheral blood showed the same genotypic pattern as did that of the thyroid lymphocytes (Fig. 4B) .
Discussion
The present study was prompted by the initial report by Knight and co-workers ( 11) indicating that TsAb measured in the LATS functional bioassay usually contained only lambda light chains. Our immunoabsorption results using the FRTL-5 cell line assay do not favor a uniform restriction of TsAb to a single lambda light chain type as can be seen in Table II. However, the results do show that in 5 of the 11 Graves' patients studied, a remarkable apparent lambda light chain predominance was present. Thus we can partially confirm the K/A Immunoglobulin Distribution in Thyroid-stimulating Antibodies 1309 initial report by Knight et al. ( 11) that a significant proportion of individual patients with TsAb appears to be restricted to Ig molecules ofthe lambda light chain class. Ofequal interest was the finding ofapparent relative kappa preponderance in only 2 of 11 Graves' patients (C and I, Table II ). This also confirms the results of Knight et al. (11) who found only 1 of 11 patients with predominant kappa Ig LATS activity. 4 of our 11 Graves' patients studied showed approximately equal TsAb activity in both kappa and lambda Ig classes. Our finding of relative lambda restriction in a significant proportion of TsAb from Graves' patients suggests that in some patients a unique predilection for lambda light chain involvement may somehow relate to the underlying disorder. Precisely how this occurs cannot at present be defined. Despite the apparent lambda restriction in five patients and kappa restriction in two, isoelectric focusing of absorbed Ig fractions produced no evidence for oligoclonal bands. It is conceivable that such Ig fractions still contain H chain subgroup restriction which would only be demonstrable by comparative serial absorptions with insoluble anti-IgG 1, 2, 3, or 4 immunoabsorbents. However, the finding that four sera showed neither kappa nor lambda Ig restriction is a strong argument against oligoclonal restriction occurring within all TsAb.
It is not surprising that TsAb as measured in the current study are not uniformly or predominantly of lambda light chain class. The patients selected by Knight et al. (11) for study of LATS activity before and after similar immunodepletion of Ig lambda or kappa molecules may have represented a relatively homogeneous group since they all showed marked elevations of LATS by biologic assay and several had pretibial myxedema. None of our patients showed the latter finding. The patients with Graves' disease that we studied showed marked elevations of cAMP-releasing activity in their serum 'v-globulin fractions but were not preselected as one subgroup within active thyrotoxicosis. Hyperthyroidism may represent a microheterogeneity of subsets of one underlying disorder. We were fully aware of this problem from the outset and in collecting samples for study, intentionally selected patients with unequivocal clinical and laboratory support for a definitive diagnosis. All Graves' patients included had diffuse goiters, (26, 27) which may also measure blocking TSH receptor activity. The problem of antibodies to the TSH receptor complex is one which has intrigued investigators for more than three decades. Initially attention was directed to LATS as an important primary criterion of Graves' disease activity (28, 29) . Later with the studies of Kohn et al. (30) (31) (32) and others (33, 34) , it became apparent that there probably exists a large repertoire of distinct antigenic epitopes actually making up TSH receptors (31, 32) . For this reason alone it would be difficult to expect that a lambda class restriction would universally apply to antibodies reacting with a spectrum of related epitopes. On the contrary, actual epitopes involved as antigens reacting with a subpopulation of autoantibodies producing positive results in the bioassay for LATS may well be much more restricted and hence induce a more clonally restricted autoimmune response in patients selected for high LATS activity. This could explain the apparent high frequency of biologically active lambda IgG molecules found by Knight et al. (10) in serum from Graves' patients with high levels of LATS activity.
Results presented here indicate that a significantly higher proportion ofGraves' disease patients have the 8-kb Eco RI CX allele than is found in the normal population. This was even more pronounced in the subset of Graves' patients with severe opthalmopathy. It is not clear how the differences in genotype described here are related to shifts in kappa/lambda ratios within autoantibodies centrally involved in the fundamental driving immunologic mechanisms of Graves' disease itself. Possibly the finding of marked lambda light chain restriction in 5 of 11 Graves' patients studied by immunoabsorption and elution assays suggests that lambda light chains perhaps with an 8/8 phenotype may be involved in the immunologic genesis of at least certain cases of thyrotoxiosis. Of interest in this regard are results recently reported by Sidebottom et al. (35) who found a marked increase in CX 8/8 phenotype and 8-kb allele among 108 unrelated patients with classical or definite rheumatoid arthritis when compared to a similar number of normal controls. These latter findings in parallel with ours suggest that several autoimmune disorders share a similar increase in expression of the 8/8 genotype and 8-kb CX allele.
The precise mechanisms actually involved in selecting out both constant and variable regions of a wide range of autoantibodies have recently been examined by a number of workers (36) (37) (38) . If indeed there is some interesting predilection for Graves' patients of a certain CX phenotype to produce autoantibodies with self-reactive specificity, such a finding (if confirmed) would be of considerable interest. The most direct way to examine this question in Graves' disease would involve definition of lambda gene arrangements from human cell lines producing monoclonal immunoglobulin G with TsAb specificity. Such an approach is presently in progress in our laboratory. A repertoire of human monoclonals with well-characterized anti-TSH receptor antibody activity has previously been extensively studied by Kohn et al. (30) (31) (32) . Thus far among these antibodies there does not appear to be any striking kappa or lambda class restriction.
The association of the 8-kb Eco RI CX allele with Graves' disease described here is of considerable interest and probably should now be analyzed with respect to HLA-DR or immunoglobulin Gm or Km allelic distributions similar to those which have been performed in the past (39) (40) (41) (42) (43) . On the basis of the findings presented here, it would now appear appropriate to again examine additional markers on lambda Ig light chains such as those recently described (44) for a possible correlation to the CX genotypic profiles described in the present study.
